{"authors": ["Knvul Sheikh"], "date_download": "2022-10-25 23:00:52", "date_modify": "2022-10-25 23:00:52", "date_publish": "2020-05-07 21:29:43", "description": "The company announced that the Food and Drug Administration had cleared its application to proceed to a clinical trial involving about 600 people.", "filename": "2020_05_07_health_coronavirus-vaccine-moderna_1666738852.html", "image_url": "https://static01.nyt.com/images/2020/05/07/science/07VIRUS-MODERNA1/07VIRUS-MODERNA1-facebookJumbo.jpg?year=2020&h=550&w=1050&s=ee22d305c7a7bc49366325492a46d70cf3404c5214906ebef0af4c66044cc25d&k=ZQJBKqZ0VN", "language": "en", "localpath": "/Users/matthewwhite/news-please-repo//data/2022/10/25/nytimes.com/2020_05_07_health_coronavirus-vaccine-moderna_1666738852.html", "title": "Moderna Gets OK to Start Larger Trial for a Coronavirus Vaccine", "title_page": "Moderna Gets OK to Start Larger Trial for a Coronavirus Vaccine - The New York Times", "title_rss": "NULL", "source_domain": "nytimes.com", "maintext": "One of the first biotech companies to begin human trials of an experimental vaccine for the coronavirus is now ready to move onto the next phase of testing.\nOn Thursday, Moderna announced that the Food and Drug Administration had cleared its application to proceed to a clinical trial involving about 600 people.\n“The imminent Phase 2 study start is a crucial step forward,” Stéphane Bancel, Moderna’s chief executive, said in a statement.\nThe main goal of this set of tests is to find out if the vaccine is safe and if positive results from the first few dozen volunteers in the first phase can be replicated in a much larger group. If it is successful, later studies, known as Phase 3 trials, will determine exactly how well the vaccine works.", "url": "https://www.nytimes.com/2020/05/07/health/coronavirus-vaccine-moderna.html"}